Baker McKenzie advised international life sciences venture capital fund Forbion as lead investor on a € 17 million Series C financing of Omeicos Therapeutics GmbH, a privately held biopharmaceutical company based in Berlin.

Forbion is contributing as the new lead investor € 12.5 million from its recently launched Forbion IV Fund to the Series C financing round. Existing Omeicos investors, Vesalius Biocapital, Remiges BioPharma, SMS Group, KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds and The Falck Revocable Trust participated in the equity financing with the remaining amount.

Baker McKenzie advised Forbion on all legal aspects related to the Series C financing.

Omeicos Therapeutics is a spin-off company from Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases.

Forbion is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives. Forbion currently manages over €1 bn across ten closed-end funds and has a team of thirteen investment professionals across two offices.

Baker McKenzie's Corporate / M&A team regularly advises financial investors on domestic and international transactions. Most recently, Baker McKenzie advised Forbion Capital Fund IV on an equity financing of Gotham Therapeutics Corporation, DBAG Fund VII on its investment in Kraft & Bauer Holding, Syngroh Capital on its investment in KMLS, financial investors First State Investments and Hermes Investment Management on the acquisition of the shipping company Scandlines from 3i Group plc, Forbion Capital Fund III on the seed and Series A financing of CatalYm and Daimler on a number of venture investments.

Legal advisor to Forbion Capital Fund IV

Lead: Julia Braun (counsel, Corporate /M&A Munich),

Team: Corporate/M&A: Nathaniel A. Douglas (associate, Washington), Matthias Schmitz (law clerk, Munich),
Intellectual Property: Fabian Boettger (counsel, Munich)
Pharma & Regulatory: Dr. Frank Pflueger (partner, Frankfurt), Dr. Martin Altschwager (senior associate, Frankfurt)
Public Law: Dr. Andreas Schulz (counsel, Berlin)
Employment: Dr. Matthias Koehler (senior associate, Berlin)

Explore Our Newsroom